Although promoter hypomethylation was found in the ARMS tumors, the M2A model correctly predicted significantly stronger promoter activities in ERMS tumors (P = 0.01, Wilcoxon rank-sum test) (Fig. 4b, d). Here, KIDINS220 is linked to embryonal rhabdomyosarcoma.